专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20160287615A1 NOVEL ENCAPSULATION OF FLUORESCENT, PHOTO-SENSITIVE, OR OXYGEN-SENSITIVE ACTIVE INGREDIENT FOR TOPICAL APPLICATION 审中-公开
标题翻译：用于局部应用的荧光，光敏性或氧气敏感性成分的新颖包封
公开(公告)号：US20160287615A1
公开(公告)日：2016-10-06
申请号：US15090595
申请日：2016-04-04
申请人： BioPharmX, Inc.
发明人： Kin F. Chan , Anja B. Krammer , Douglas W. Thomas
IPC分类号： A61K31/65 , A61K9/50 , A61K31/66 , A61K9/00
CPC分类号： A61K31/65 , A61K9/14
摘要： A topical composition for treatment of a skin condition comprising a fluorescent, photosensitive, or oxygen sensitive active ingredient encapsulated in a plurality of tubular microparticles for pharmaceutical use in humans is described. Some embodiments comprise a topical composition for treatment of acne that comprises an encapsulation of a tetracycline class drug, such as crystalline minocycline, in a plurality of microparticles, wherein the microparticles comprise a divalent cation, such as Mg2+ or Zn2+. The tubular microparticles may comprise Mg2CO3. Benefits of various embodiments include the lack of visible fluorescence from a fluorescent active ingredient, reduced UV degradation of a photosensitive active ingredient, reduced UV degradation of an oxygen sensitive active ingredient, sun protection factor for the skin, and sustained delivery of a therapeutic dose.
摘要翻译：描述了用于治疗皮肤病症的局部组合物，其包含包封在用于人类药物的多个管状微粒中的荧光，感光或氧敏感性活性成分。一些实施方案包括用于治疗痤疮的局部组合物，其包含将四环素类药物如结晶米诺环素包封在多个微粒中，其中所述微粒包含二价阳离子，例如Mg 2+或Zn 2+。管状微粒可以包含Mg 2 CO 3。各种实施方案的优点包括缺乏来自荧光活性成分的可见荧光，光敏活性成分的UV降解降低，氧敏感性成分的UV降解，皮肤的防晒因子和治疗剂量的持续递送。

82. 发明授权

US09421271B2 Sustained-release drug carrier composition 有权
标题翻译：持续释放药物载体组成
公开(公告)号：US09421271B2
公开(公告)日：2016-08-23
申请号：US14523894
申请日：2014-10-26
申请人： POLYPID LTD.
发明人： Noam Emanuel
IPC分类号： A61F2/28 , A61K47/34 , A61K47/24 , A61L31/16 , A61L27/18 , A61L27/54 , A61L27/58 , A61L31/06 , A61K9/00 , A61K31/192 , A61K31/427 , A61K31/65 , A61K47/22 , A61K47/28 , A61K47/42 , A61K31/56 , A61L31/10
CPC分类号： A61K47/24 , A61K9/0087 , A61K31/192 , A61K31/427 , A61K31/56 , A61K31/65 , A61K47/22 , A61K47/28 , A61K47/34 , A61K47/42 , A61L27/18 , A61L27/54 , A61L27/58 , A61L31/06 , A61L31/10 , A61L31/16 , A61L2300/204 , A61L2300/222 , A61L2300/404 , A61L2300/406 , A61L2300/41 , A61L2300/412 , A61L2300/602 , A61L2300/606 , A61L2300/802 , A61L2420/04 , C08L67/04
摘要： The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
摘要翻译：本发明提供了用于延长释放活性成分的组合物，其包含由可生物降解的聚合物形成的脂质饱和基质。本发明还提供了生产基质组合物的方法和使用该基质组合物来提供活性成分在有需要的受试者体内的受控释放的方法。

83. 发明申请

US20160235675A1 Technology for the Preparation of Microparticles 审中-公开
公开(公告)号：US20160235675A1
公开(公告)日：2016-08-18
申请号：US15080399
申请日：2016-03-24
申请人： Ansun Biopharma, Inc.
发明人： Michael P. Malakhov , Fang Fang
IPC分类号： A61K9/16 , A61K38/18 , A61K38/38 , A61K38/48 , A61K38/17 , A61K38/46 , A61K38/42 , A61K38/14 , A61K31/7036 , A61K31/43 , C12N15/113 , C12N7/00 , A61K38/08 , A61K38/12 , A61K31/65 , A61K31/337 , A61K31/5575 , A61K31/721 , A61K31/724 , A61K31/198 , A61K31/405 , A61K38/47
CPC分类号： A61K9/1682 , A61K9/0048 , A61K9/0075 , A61K9/1652 , A61K9/1658 , A61K9/19 , A61K9/5089 , A61K31/198 , A61K31/337 , A61K31/343 , A61K31/405 , A61K31/43 , A61K31/555 , A61K31/557 , A61K31/5575 , A61K31/65 , A61K31/7036 , A61K31/721 , A61K31/724 , A61K35/76 , A61K38/08 , A61K38/12 , A61K38/14 , A61K38/168 , A61K38/1709 , A61K38/1808 , A61K38/38 , A61K38/385 , A61K38/42 , A61K38/465 , A61K38/47 , A61K38/4826 , C07D305/14 , C07K9/008 , C07K14/765 , C12N7/00 , C12N9/96 , C12N15/113 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/50 , C12N2330/30 , C12N2770/00021 , C12N2770/00051 , C12Y301/21001 , C12Y301/27005 , C12Y302/00 , C12Y302/01017 , C12Y302/01018 , C12Y304/21004 , Y02A50/385 , Y02A50/387 , Y02A50/393 , Y02A50/401 , Y02A50/402 , Y02A50/411 , Y02A50/469 , Y02A50/47 , Y02A50/471 , Y02A50/478 , Y02A50/481 , Y02A50/483 , Y02A50/49 , Y02A50/491
摘要： Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

84. 发明申请

US20160222061A1 Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics 审中-公开
标题翻译：多粘菌素衍生物及其联合治疗与不同抗生素联用
公开(公告)号：US20160222061A1
公开(公告)日：2016-08-04
申请号：US14892757
申请日：2014-05-21
申请人： NEW PHARMA LICENCE HOLDINGS LIMITED
发明人： Pamela Brown , Michael Dawson , Mona Simonovic , Steven Boakes , Esther Duperchy
IPC分类号： C07K7/62 , A61K31/496 , A61K31/65 , A61K31/575 , A61K31/427 , A61K31/7052 , A61K31/431 , A61K31/7048 , A61K38/08 , A61K31/407
CPC分类号： C07K7/62 , A61K31/407 , A61K31/427 , A61K31/431 , A61K31/496 , A61K31/575 , A61K31/65 , A61K31/7048 , A61K31/7052 , A61K38/00 , A61K38/08
摘要： Described are compounds of formula (I) for use in combination treatment with a second active agent, such as rifampicin, for example for treatment of a microbial infection. The compound of formula (I) is a polymyxin compound is: where the groups -A-, —R1, —R2, —R3, —R4, —R5, —R6, —R7, —R8, and —X— are described in detail within the description.
摘要翻译：描述了用于与第二活性剂如利福平组合治疗的式（I）化合物，例如用于治疗微生物感染。式（I）化合物是多粘菌素化合物，其中描述了基团-A-，-R1，-R2，-R3，-R4，-R5，-R6，-R7，-R8和-X- 在描述中详细描述。

85. 发明申请

US20160169889A1 DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASE USING URINE SPECIMENS 审中-公开
标题翻译：使用尿液样本诊断呼吸道感染性疾病
公开(公告)号：US20160169889A1
公开(公告)日：2016-06-16
申请号：US15047983
申请日：2016-02-19
申请人： Mochida Pharmaceutical Co., Ltd.
发明人： Kamon Shirakawa
IPC分类号： G01N33/569 , A61K31/665 , A61K31/65 , A61K31/7008 , A61K31/7028 , A61K31/43 , A61K38/02
CPC分类号： G01N33/56911 , A61K31/407 , A61K31/43 , A61K31/65 , A61K31/665 , A61K31/7008 , A61K31/7028 , A61K38/02 , A61K38/16 , A61K45/00 , G01N2333/70596 , G01N2800/12 , G01N2800/52
摘要： Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.
摘要翻译：提供了一种检测与细菌感染相关的呼吸道感染的方法，选择呼吸道感染患者以接受抗生素的方法，以及用于确定终止对接受抗生素的呼吸道感染的患者施用抗生素的时间的方法，其中所述方法的特征在于它们能够适当选择要施用抗生素的呼吸道感染患者，以调节抗生素的施用时间，并治疗与细菌感染相关的呼吸道感染，并且测量值使用尿液中的sCD14-ST作为指标。

86. 发明申请

US20160151397A1 DOXYCYCLINE COMPOSITION 有权
标题翻译： DOXYCYCLINE组合物
公开(公告)号：US20160151397A1
公开(公告)日：2016-06-02
申请号：US15013122
申请日：2016-02-02
申请人： SUN PHARMACEUTICAL INDUSTRIES LIMITED
发明人： Ravish Kumar SHARMA , Pulak Kumar METIA , Ravinder SINGH , Rajesh Srikrishan SHEAR , Anuj Kumar FANDA , Satish Kumar JAIN , Romi Barat SINGH , Swarna PAPPU , Prabhakar KONATHAM , Pruthvipathy KATIKANENI , Dileep JAMI
IPC分类号： A61K31/65 , A61K9/16
CPC分类号： A61K31/65 , A61K9/1676 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/209
摘要： The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.
摘要翻译：本发明涉及一种每日一次的药物组合物，其包含多西环素，受控释放聚合物和一种或多种药学上可接受的赋形剂。本发明还提供了通过施用这种药物组合物治疗酒渣鼻的方法。还提供了制备这种药物组合物的方法。

87. 发明申请

US20160151396A1 PHARMACEUTICAL COMPOSITION OF DOXYCYCLINE WITH REDUCED FOOD EFFECT 有权
标题翻译：具有减少食物作用的DOXYCYCLINE药物组合物
公开(公告)号：US20160151396A1
公开(公告)日：2016-06-02
申请号：US15013097
申请日：2016-02-02
申请人： SUN PHARMACEUTICAL INDUSTRIES LIMITED
发明人： Ravish Kumar SHARMA , Pulak Kumar METIA , Ravinder SINGH , Rajesh Srikrishan SHEAR , Anuj Kumar FANDA , Satish Kumar JAIN , Romi Barat SINGH , Swarna PAPPU , Prabhakar KONATHAM , Pruthvipathy KATIKANENI , Dileep JAMI
IPC分类号： A61K31/65 , A61K9/16
CPC分类号： A61K31/65 , A61K9/1676 , A61K9/2027 , A61K9/2054 , A61K9/2081 , A61K9/209
摘要： The present invention relates to a once daily pharmaceutical composition comprising doxycycline and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline pharmaceutical composition with or without food. A process of preparing such pharmaceutical composition is also provided.
摘要翻译：本发明涉及一种每日一次的药物组合物，其包含多西环素和一种或多种药学上可接受的赋形剂，其中所述药物组合物显示降低的食物效应。本发明还提供了一种通过向有需要的人施用具有或不具有食物的多西环素药物组合物来治疗酒渣鼻的方法。还提供了制备这种药物组合物的方法。

88. 发明申请

US20160144036A1 TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION 审中-公开
公开(公告)号：US20160144036A1
公开(公告)日：2016-05-26
申请号：US15010116
申请日：2016-01-29
申请人： Wyeth LLC
发明人： Mahdi B. FAWZI , Tianmin ZHU , Syed M. SHAH
IPC分类号： A61K47/26 , A61K47/02 , A61K31/65
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/08 , A61K9/19 , A61K31/65 , A61K47/02
摘要： The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.

89. 发明申请

US20160143925A1 STABLE PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：稳定的药物组合物
公开(公告)号：US20160143925A1
公开(公告)日：2016-05-26
申请号：US14897788
申请日：2014-11-12
申请人： GALENICUM HEALTH S.L.
发明人： Sergio ARROYO HIDALGO , Mireia PLADEVALL ROSÉS
IPC分类号： A61K31/65 , A61K9/19 , A61K47/18
CPC分类号： A61K31/65 , A61K9/0019 , A61K9/08 , A61K9/1682 , A61K9/19 , A61K38/05 , A61K47/02 , A61K47/183
摘要： The present invention relates to a stable pharmaceutical composition comprising tigecycline and arginine, to a process for the manufacture of said pharmaceutical composition as well as to its use in the treatment of bacterial infections.
摘要翻译：本发明涉及包含替加环素和精氨酸的稳定的药物组合物，涉及制备所述药物组合物的方法以及其在治疗细菌感染中的用途。

90. 发明申请

US20160136186A1 DIRECT MEDICAMENT PERIODONTAL DELIVERY METHOD AND ASSEMBLY FOR REDUCTION OF THE SYSTEMIC INFLAMMATORY MARKERS 审中-公开
标题翻译：直接药物周边递送方法和组装用于减少系统性炎症标记
公开(公告)号：US20160136186A1
公开(公告)日：2016-05-19
申请号：US14946622
申请日：2015-11-19
申请人： Duane C. Keller
发明人： Duane C. Keller
IPC分类号： A61K31/65 , A61K9/00 , A61K33/40
CPC分类号： A61K31/65 , A61K9/0063 , A61K33/40 , A61K2300/00
摘要： Methods and systems for reducing an identified systemic inflammatory marker associated with cardiovascular disease in a patient is provided through periodontal treatment that includes identifying an oral periopathogen related to the systemic inflammatory marker and a biofilm and an environment associated with the periopathogen, preparing a periodontal tray for direct application of a selected medicament having a efficacy in regard to the identified oral periopathogen and biofilm of the gum tissue associated with the one application region in which the medicament is to be placed and applying the tray with the placed selected medicament to the treatment region of the patient such that at least a portion of the selected medicament is forced into a gingival sulcus or periodontal pocket of the gum tissue of the treatment region and monitoring and continuing treatment to reduce the identified systemic inflammatory marker.
摘要翻译：通过牙周治疗来提供减少与患者心血管疾病相关的全身性炎性标志物的方法和系统，该牙周治疗包括鉴定与全身炎症标志物相关的口腔周围病原体，以及生物膜和与病原体相关的环境，制备牙周托盘直接施用选择的药物，其具有关于鉴定的口服periopathogen和与其中将要放置药物的一个施用区域相关联的牙龈组织的生物膜的效力，并将具有放置的选定药物的托盘施用于治疗区域所述患者使得所选择的药物的至少一部分被迫进入治疗区域的牙龈组织的牙龈沟或牙周袋，并监测并继续治疗以减少所鉴定的全身炎症标记物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式